Clinical Research Details Clinical Research Efficacy and safety investigation of NNC0194-0499 co-administered with semaglutide in subjects with non-alcoholic steatohepatitis a dose-ranging, placebo controlled trial Study Description NASH is a disease where fat, inflammation and scar tissue build up in the liver. These cause liver damage and can lead to complications. We are doing this study to see if a combination of 2 medicines (NNC0194-0499 and semaglutide or semaglutide and NNC0174-0833) can reduce liver damage in patients with NASH. Inclusion/Exclusion Criteria You must have NASH on a liver biopsy to take part in this study. You will need to have stage 2, 3, or 4 fibrosis. When the study looks at your liver biopsy, you have to have a certain score to be in the study. You cannot be in this study if you have liver disease due to something other than NASH. You cannot be in this study if you have a hepatitis infection or HIV. You cannot be in this study if your liver disease is too far advanced. You cannot be in this study if you drink too much alcohol. You cannot be in the study if you take medications called GLP-1 RAs for Type 2 Diabetes. You cannot be in this study if your diabetes medications have changed a lot recently. Investigators Maged P. Ghali, M.D. Medicine